Kiumars Arfai, MD
Pain Medicine · Mission Hills, CANPI 1407804370
Payments from drug & device makers
Across 374 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Collegium Pharmaceutical, Inc.$1K
- Boston Scientific$908
- Biotronik NRO, Inc.$442
- Curonix LLC$339
- Stimwave Technologies Incorporated$291
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1322%
- Food & beverage$8,39798%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 154 | $3,800 |
| Collegium Pharmaceutical, Inc. | 64 | $1,168 |
| Boston Scientific | 28 | $908 |
| Biotronik NRO, Inc. | 8 | $442 |
| Curonix LLC | 15 | $339 |
| Stimwave Technologies Incorporated | 21 | $291 |
| Nalu Medical, Inc. | 15 | $242 |
| Vertex | 6 | $159 |
| Daiichi Sankyo Inc. | 8 | $124 |
| Biodelivery Sciences International, Inc. | 7 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $109 |
| Si-bone, Inc. | 1 | $98 |
| Stryker | 4 | $87 |
| Avanos Medical | 5 | $83 |
| Scilex Pharmaceuticals Inc. | 5 | $77 |
| Globus Medical | 2 | $72 |
| Medtronic(2 entities) | 4 | $70 |
| Painteq LLC | 2 | $55 |
| Johnson & Johnson | 3 | $45 |
| Fidia Pharma USA Inc. | 2 | $39 |
| Sentynl Therapeutics, Inc. | 2 | $27 |
| Vertos Medical, Inc. | 1 | $25 |
| Assertio Therapeutics, Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $21 |
| Nevro Corp. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
| AbbVie | 1 | $13 |
| Forte Bio-pharma LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Penta SCS Leads$536
- Prospera$163
- Proclaim Family of SCS IPGs$160
- SUPERION$132
- PROCLAIM$117
How this compares
$8,563 in reported general payments places this provider in the 75th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Potassium | 153 | $282,251 |
| Chlorzoxazone | 117 | $266,488 |
| Diclofenac Sodium | 194 | $214,165 |
| Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag | 58 | $112,355 |
| Dermacinrx LidocanLidocaine | 14 | $104,803 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 27 | $64,389 |
| Diclofenac Epolamine | 60 | $59,269 |
| OxycontinOxycodone Hcl | 47 | $54,232 |
| Lidocaine | 157 | $26,477 |
| BelbucaBuprenorphine Hcl | 32 | $26,306 |
| Doxepin Hcl | 11 | $22,949 |
| Xtampza ErOxycodone Myristate | 22 | $20,064 |
| MounjaroTirzepatide | 17 | $16,911 |
| MovantikNaloxegol Oxalate | 29 | $12,318 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 474 | $11,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,168 | $46,37154 claims |
| Redhill Biopharma Inc.Movantik | $21 | $12,31829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 pain medicine providers in California.
Other pain medicine in Mission Hills
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.